Loading
Mogamulizumab is an antibody that clears cancerous T cells from the blood in mycosis fungoides and Sézary syndrome, the leukaemic form of skin lymphoma.
MAVORIC (2018): PFS 7.7 vs 3.1 months versus vorinostat, with the best responses in blood compartment and Sézary syndrome. Approved in Japan (2012) for ATLL and CCR4+ PTCL/CTCL; US/EU 2018 for MF/SS after one systemic therapy. Rash (mogamulizumab-associated rash) and increased GVHD risk after subsequent allogeneic transplant.
Backbone ribbon from PDB 9ULL. RCSB PDB 9ULL. The ribbon widens where the chain is folded into a regular pattern and narrows where it is a loose loop.
Binds CCR4 on malignant T cells (and regulatory T cells) and kills them through enhanced ADCC from the afucosylated Fc. Connects to CCR4.
1.Mogamulizumab binds CCR4.
Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies.
Covered under the medical benefit with prior authorisation confirming diagnosis, biomarker status and line of therapy; site-of-care policies may steer infusions away from hospital outpatient departments.
20% Part B coinsurance on a high-cost infusion adds up quickly: Medigap Plan G or N, Medicare Advantage maximum out-of-pocket, Medicaid dual eligibility, or a charity fund are the usual buffers.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.
Sources: NICE TA754. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| JP | 2012 | Relapsed CCR4+ adult T-cell leukaemia/lymphoma; later PTCL/CTCL |
| US | 2018 | Relapsed/refractory mycosis fungoides or Sézary syndrome after ≥1 systemic therapy |
| EU | 2018 | MF/SS after ≥1 systemic therapy |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Mogamulizumab" OR ABSTRACT:"Mogamulizumab" OR TITLE:"Poteligeo" OR ABSTRACT:"Poteligeo") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Mogamulizumab, not a curated reading list.
Shares MAVORIC: mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma, MAVORIC, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma).
Shares MAVORIC: mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma, MAVORIC, Mycosis fungoides, Sezary syndrome.
Shares Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma, Mycosis fungoides, Sezary syndrome, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Shares ADCC (antibody-dependent cellular cytotoxicity), Sezary syndrome, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma).
Shares Mycosis fungoides, What the NHS in England funds for lymphoma, appraisal by appraisal, Sezary syndrome, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Shares Fc engineering / effector function, ADCC (antibody-dependent cellular cytotoxicity), Monoclonal antibodies.
Shares Sezary syndrome, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma).
Shares Mycosis fungoides, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma).